Mean age | 58.4 (range 44–77) | |||
---|---|---|---|---|
N = 25 | % | |||
Sex | Male | 17 | 68 | |
Female | 8 | 32 | ||
TNM Stage | T | X | 4 | 16 |
0 | 0 | 0 | ||
1 | 4 | 10 | ||
2 | 7 | 28 | ||
3 | 7 | 28 | ||
4 | 3 | 12 | ||
N | X | 0 | 0 | |
0 | 18 | 72 | ||
1 | 0 | 0 | ||
2 | 7 | 28 | ||
M | 0 | 0 | 0 | |
1 | 25 | 100 | ||
Histology | Clear cell | 21 | 84 | |
Papillary | 4 | 16 | ||
Sites of disease | Lung | 16 | 64 | |
Lymph node | 9 | 36 | ||
Soft tissue | 7 | 28 | ||
Bone | 6 | 24 | ||
Kidney | 5 | 20 | ||
Liver | 5 | 20 | ||
Pancreas | 2 | 8 | ||
Adrenal | 1 | 4 | ||
Prior Therapy | Nephrectomy | 23 | 92 | |
Chemotherapy | 8 | 32 | ||
Immunotherapy | 10 | 40 | ||
Radiation therapy | 2 | 8 | ||
Cryoablation | 1 | 4 | ||
Laser ablation | 1 | 4 | ||
Treatment Characteristics | ||||
Vaccination | ≤ 2 | 3 | 12 | |
3–5 | 14 | 56 | ||
≥ 6 | 8 | 32 | ||
No. of IL-2 Cycles | 1 | 4 | 16 | |
2 | 9 | 36 | ||
3 | 0 | 0 | ||
4 | 9 | 36 |